Vorolanib: all 29 studies that test it
Page 1 of 1. Open to participants first (5), then studies with results posted, then the rest; newest registration first within each.
- Pharmacokinetic Study of Vorolanib Tablets in Trial Participants With Hepatic ImpairmentRecruitingNCT07809802Phase 1
- A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKINot yet recruitingNCT07165418Phase 3
- Vorolanib Combined With Cadonilimab in the Treatment of Untreated Advanced RCC PatientsNot yet recruitingNCT06577961Phase 1/2
- Vorolanib Plus Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitors Based Combination TherapyNot yet recruitingNCT06523049Phase 2
- A Phase II Clinical Study of Cadonilimab in Treatment-naïve or Relapsed Extensive Small Cell Lung CancerRecruitingNCT06406673Phase 2
- Study of EYP-1901 in Patients With Nonproliferative Diabetic Retinopathy (NPDR)CompletedNCT05383209Phase 2Results posted
- Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD)CompletedNCT05381948Phase 2Results posted
- Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung CancerTerminatedNCT04373369Phase 2Results posted
- Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic TumorsCompletedNCT03583086Phase 1/2Results posted
- COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DMEActive, not recruitingNCT07449936Phase 3
- CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DMEActive, not recruitingNCT07449923Phase 3
- Vorolanib Monotherapy or in Combination With Toripalimab as Adjuvant Therapy for Patients With Intermediate-high Risk of Recurrence in Renal Cell CarcinomaActive, not recruitingNCT07047001Phase 2
- A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56Active, not recruitingNCT06683742Phase 3
- A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56Active, not recruitingNCT06668064Phase 3
- Study of EYP-1901 in Patients With Diabetic Macular Edema (DME)CompletedNCT06099184Phase 2
- First in Human Study to Evaluate the Safety and Tolerability of EYP-1901 in Patients With Wet Age Related Macular Degeneration (wAMD)CompletedNCT04747197Phase 1
- The Absorption, Metabolism and Excretion of [14C]CM082 in HumanCompletedNCT04434326Phase 1
- Bioequivalency Study of CM082 Tablet in Healthy VolunteersCompletedNCT04328506Phase 1
- CM082 in Patients With Myopic Choroidal Neovascularization (CNV)SuspendedNCT04222842Phase 1
- CM082 and JS001 in Patients With Advanced Small-cell Lung Cancer (SCLC)Status unknownNCT03904719Phase 2
- CM082 and JS001 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC).Status unknownNCT03848611Phase 2
- Study of Challenge Meditech 082 (CM082) Tablets in Patients With Advanced Malignant Solid TumorsStatus unknownNCT03792958Phase 1
- Safety and Tolerability of Oral CM082 in Patients With wAMDStatus unknownNCT03710863Phase 2
- Study of the Combination of CM082 With JS001 in Patients With Advanced Mucosal Melanoma.Status unknownNCT03602547Phase 2
- Second-line CM082 Combined With Paclitaxel For Patients With Advanced Gastric CancerStatus unknownNCT03286244Phase 1
- CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell CarcinomaStatus unknownNCT03095040Phase 3
- Study of the Combination of CM082 With Everolimus in Patients With mRCCStatus unknownNCT02577458Phase 1
- Phase 1 Study of CM082 in Patients With wAMDSuspendedNCT02452385Phase 1
- Phase 1 Study of CM082 (X-82) Tablets in Advanced Cancer Patients in ChinaCompletedNCT01863485Phase 1